Atrial fibrillation (AF) is associated with structural, electrical, and contractile remodeling of the atria. Development and progression of atrial fibrosis is the hallmark of structural remodeling in AF and is considered the substrate for AF perpetuation. In contrast, experimental and clinical data on the effect of ventricular fibrotic processes in the pathogenesis of AF and its complications are controversial. Ventricular fibrosis seems to contribute to abnormalities in cardiac relaxation and contractility and to the development of heart failure, a common finding in AF. Given that AF and heart failure frequently coexist and that both conditions affect patient prognosis, a better understanding of the mutual effect of fibrosis in AF and heart failure is of particular interest. In this review paper, we provide an overview of the general mechanisms of cardiac fibrosis in AF, differences between fibrotic processes in atria and ventricles, and the clinical and Table 1 ); TAK1 ¼ transforming growth factor beta-1 activated kinase 1; TbRI ¼ type I transforming growth factor beta-1 receptor; TbRII ¼ type II transforming growth factor beta-1 receptor;
Although collagen deposition in the healthy heart is restricted to maintenance of heart architecture, during progression of various cardiac disorders, the collagen network undergoes quantitative and qualitative changes leading to excessive accumulation of collagen, either in regions of cardiomyocyte loss (e.g., in myocardial infarction, reparative fibrosis) or diffusely, in areas of the myocardium not involved in the focal injury (e.g., in dilated cardiomyopathy, reactive fibrosis) (4, 5) .
CARDIAC FIBROBLASTS AND MYOFIBROBLASTS. Both cellular and extracellular components take part in the remodeling process. Cardiac fibroblasts play a pivotal role in formation of the ECM. They are numerous within the myocardium and can account for up to 60% of cells in cardiac muscle (6) . Thus, cardiac fibroblasts outnumber even cardiomyocytes, although the latter cells largely determine total myocardial mass.
The population of cardiac fibroblasts in healthy adult hearts is maintained at a relatively low level and is predominantly composed of resident fibroblasts and cells undergoing an epithelial-tomesenchymal transition. In pathological conditions, fibroblasts dramatically increase in number via differentiation from several cell lineages, including monocytes, endothelial cells, bone marrow-circulating progenitor cells, and pericytes (7-9). Myofibroblasts are cells that play a particularly significant role in cardiac fibrosis. They are derived from cardiac fibroblasts but have an w2-fold higher capacity to synthesize collagen. Compared with cardiac fibroblasts, myofibroblasts do not appear in healthy myocardium, are more responsive to proinflammatory and profibrotic stimuli, and are capable of synthesizing a large variety of cytokines and chemokines (13) . Importantly, myofibroblasts contain alpha-smooth muscle actin and adhesion complexes (fibronexus). The latter binds myofibroblast internal microfilaments to ECM proteins that help to provide contractile force to the surrounding ECM.
A range of growth factors, cytokines, and hormones, as well as mechanical stretch and hypoxia, regulate ECM turnover and cardiac fibroblast activity. and promotes MMP2 expression (36, 37) . Interestingly, it also produces protective effects, including defense against oxidative stress, inhibition of proapoptotic factors, and increased expression of antiapoptotic genes (38) . Finally, miR-29 is associated with deposition of collagen types I and III. Up-regulation of miR-29 leads to down-regulation of these proteins and vice versa (39) .
INFLAMMATION. AF is common in patients with overt inflammatory states of cardiac and noncardiac location (e.g., myocarditis, pericarditis, pneumonia, and inflammatory bowel disease), but low-grade subclinical inflammation (e.g., in coronary heart disease) also contributes to pathogenesis of the arrhythmia ( Figure 2) There are also differences between cardiomyocytes and cardiofibroblasts in receptor density and receptor kinase activity, which may interfere with the final effects of effector molecules. For example, fibroblasts are known to carry more angiotensin II receptors than cardiomyocytes (49) . Multiple other regulatory substances are implicated in the interplay between fibroblasts and cardiomyocytes (e.g., fibroblast growth factor 2, interleukins, natriuretic peptides, and miRs) (48) . Some stimuli are attributed predominantly to fibroblasts (e.g., platelet-derived growth factor
[PDGF], fibroblast growth factor 2, and activation by mechanical stretching), whereas abnormalities in calcium handling are largely seen in cardiomyocytes (50) .
Cardiac remodeling requires fibrosis as an essential component and is a complex process that also incorporates multiple other pathways, such as hypoxia signaling, the osteoprotegerin/RANK/RANKL axis, and Ca 2þ signaling. A detailed description of these pathways is beyond the scope of the current review.
In summary, the ECM is a macromolecular, metabolically active, dynamic network of fibers (predominantly collagen) and cells (predominantly cardiac fibroblasts with a capacity to differentiate into myofibroblasts) that is essential for normal heart function. 
ATRIAL FIBROSIS IN AF
A variety of signaling systems are involved in the promotion of atrial fibrosis, as evidenced by numerous human and animal data ( Tables 1 and 2) . 
EXTRACARDIAC AND GENETIC FACTORS CONTRIBUTING TO ATRIAL FIBROSIS
Multiple noncardiac factors predispose to fibrosis in AF, including obesity, metabolic syndrome, use of toxic substances, athlete's heart, obstructive sleep apnea, systemic inflammation, and thyrotoxicosis. All of these factors ultimately affect the myocardium (62) . Recently, diabetes, a disease associated specifically with cardiomyopathy and excessive cardiac fibrosis, was shown to triple the risk of AF in obese subjects (63) . Obesity leads to electrical and structural atrial remodeling and is associated with diastolic ventricular impairment, atrial dilation, and myocardial lipidosis (64) . Obesity in AF is related to delay and significant heterogeneity in atrial conduction, atrial inflammatory infiltration, and interstitial fibrosis. Pathways underlying these changes include activation of TGF-b 1 signaling, oxidative stress, and Tables 1 and 2 . specific relevance in the context of AF remains to be established (93, 94) .
Collagen turnover markers of prognostic significance were assessed in hypertensive heart disease, hypertrophic cardiomyopathy, and HF (95, 96) . However, the major limitation of blood markers of collagen turnover is that they are not cardiac-specific and may not accurately reflect myocardial collagen content. Hence, the results are often conflicting, depending largely on the selection of study cohorts 
